Welcome to our dedicated page for Praxis Precision Medicines news (Ticker: PRAX), a resource for investors and traders seeking the latest updates and insights on Praxis Precision Medicines stock.
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for central nervous system (CNS) disorders characterized by neuronal imbalance. By leveraging genetic insights, Praxis aims to address conditions ranging from major depressive disorder to epilepsy.
The company's lead product candidates include:
- Prax-114: An extrasynaptic-preferring GABAA receptor positive allosteric modulator, currently in Phase IIa trials for treating major depressive disorder and perimenopausal depression.
- Prax-944: A selective small molecule inhibitor of T-type calcium channels, in Phase IIa trials for essential tremor treatment.
- Prax-562: A persistent sodium current blocker in Phase I trials aimed at severe pediatric epilepsy and adult cephalgia.
- Prax-222 (Elsunersen): An antisense oligonucleotide targeting gain-of-function SCN2A epilepsy, under collaboration with Ionis Pharmaceuticals and RogCon, Inc.
- PRAX-628: A next-gen small molecule targeting sodium-channels in the brain, being developed as a treatment for focal epilepsy.
- Ulixacaltamide: A small molecule inhibitor for essential tremor, currently in late-stage development.
Recent news highlights include a partnership with Tenacia to extend ulixacaltamide's reach to Greater China, and advances in the PRAX-628 program demonstrating its potential as a best-in-class epilepsy drug.
Financially, Praxis has shown significant progress. As of the latest reports, the company has sufficient funding to continue operations into 2027, driven by strategic public offerings and a lean operational model.
For more details, visit www.praxismedicines.com and follow them on social media channels.
PRAX-944 has shown promising results in the Phase 2a study for treating essential tremor (ET). A mean improvement of 42% in the Modified Activities of Daily Living score was observed by Day 42, with a significant distinction during the randomized withdrawal phase. The treatment was well-tolerated with no new safety findings. Following these results, Praxis intends to update the primary endpoint for the Phase 2b Essential1 study to focus on efficacy, indicating progress towards a potential treatment for ET patients.
Praxis Precision Medicines (NASDAQ: PRAX) announced participation in a fireside chat at the BofA Securities 2022 Healthcare Conference on May 11, 2022, at 5:00 p.m. ET. The event will be accessible via live webcast on the company's website, with a replay available for 90 days post-event. Praxis focuses on developing therapies for central nervous system disorders linked to neuronal excitation-inhibition imbalance, leveraging genetic insights. The company has multiple clinical-stage product candidates addressing psychiatric and movement disorders, and epilepsy.
Praxis Precision Medicines (NASDAQ: PRAX) announced a corporate update and financial results for Q1 2022 set for May 9, 2022, post-market close. The management will share a video highlighting business and pipeline progress, followed by a live Q&A at 4:30 p.m. ET. Praxis is focused on developing therapies for CNS disorders linked to neuronal imbalances and boasts a broad portfolio, including multiple clinical-stage product candidates addressing various neurological and psychiatric disorders. For more, visit Praxis Medicines.
Praxis Precision Medicines hosted its 2022 Epilepsy Day in New York City, showcasing its advancements in treating CNS disorders. CEO Marcio Souza highlighted their innovative approaches and significant progress across three major epilepsy programs: PRAX-222, PRAX-562, and PRAX-628, all expected to reach clinical stages by the end of 2022. The company aims to address unmet needs in epilepsy management with targeted therapies. This event emphasized Praxis' multi-billion-dollar market opportunity in the epilepsy sector, reflecting its commitment to rapid drug development driven by genetic insights.
Praxis Precision Medicines (NASDAQ: PRAX) has announced an upcoming Epilepsy Day on April 27, 2022, from 8:30 a.m. to 11:30 a.m. ET, held virtually and in New York City. This event will highlight the company's extensive epilepsy pipeline, the largest in the industry, and discuss clinical and regulatory strategies. Key opinion leaders like Dr. Jacqueline French and Dr. Daniel Friedman will share insights on advancements in epilepsy and unmet patient needs. A live webcast will be available on their website, with a replay accessible for 90 days.
Praxis Precision Medicines (NASDAQ: PRAX) has announced that data from its PRAX-944 essential tremor (ET) program will be showcased at the 2022 American Academy of Neurology Annual Meeting in Seattle from April 2-7, and virtually from April 24-26. Chief Medical Officer Bernard Ravina highlighted the need for better therapeutic options for ET, as current treatments often have poor tolerability. PRAX-944, a T-type calcium channel blocker, has shown promise in reducing tremor symptoms with acceptable safety profiles. The oral presentation is scheduled for April 6 at 5:06 PM PT.
Praxis Precision Medicines (NASDAQ: PRAX) announced its participation in a fireside chat at Stifel’s 4th Annual CNS Day on March 29, 2022, at 11:30 a.m. ET. The event will be accessible through a live webcast on the company’s website, with a replay available for 90 days post-event. Praxis focuses on developing therapies for central nervous system disorders by leveraging genetic insights into neuronal excitation-inhibition imbalances, targeting both rare and prevalent neurological and psychiatric conditions. For more details, visit www.praxismedicines.com.
Praxis Precision Medicines (NASDAQ: PRAX) will participate in the Neuropsych panel at Cowen’s 42nd Annual Healthcare Conference on March 7, 2022, at 9:10 a.m. ET. The event will be accessible via live webcast on the company's website, with a replay available for 30 days post-event. Praxis focuses on developing therapies for CNS disorders using genetic insights, addressing conditions such as epilepsy, psychiatric, and movement disorders. They currently have three clinical-stage product candidates.
Praxis Precision Medicines (NASDAQ: PRAX) provided a corporate update and reported financial results for Q4 and full year 2021. The company expects topline results for PRAX-114 Phase 2/3 Aria Study for Major Depressive Disorder in June 2022. As of December 31, 2021, Praxis had $275.9 million in cash, funding operations into Q2 2023. R&D expenses rose to $120.3 million for 2021, up from $45 million in 2020. Net loss for 2021 was $167.1 million, compared to $61.8 million the previous year. Upcoming milestones include multiple study results for psychiatric and movement disorders.
Praxis Precision Medicines (NASDAQ: PRAX) announced on February 22, 2022, that it will release its fourth quarter and full year 2021 financial results on February 28, 2022, prior to U.S. market opening. The company will provide a corporate update and report on recent business and pipeline advancements through a video presentation. Afterward, a live Q&A session will be held at 8:30 a.m. ET. Praxis focuses on developing therapies for CNS disorders linked to neuronal excitation-inhibition imbalance, with three clinical-stage product candidates.
FAQ
What is the current stock price of Praxis Precision Medicines (PRAX)?
What is the market cap of Praxis Precision Medicines (PRAX)?
What does Praxis Precision Medicines, Inc. specialize in?
What are the primary product candidates of Praxis?
What is the status of Prax-114?
How is Praxis advancing its epilepsy treatments?
What are recent corporate milestones for Praxis?
Can you provide financial details on Praxis' operations?
How can I stay updated on Praxis' developments?
What partnerships has Praxis recently announced?
What is Ulixacaltamide, and what is its current development stage?
Where can I find more information about Praxis' clinical studies?
